Industry Research

  1. A Look At 2018’s CDMO Expansions
    12/3/2018

    ISR looked at each month in the past year to identify the biggest expansion news announced by large CDMOs.

  2. Decision-making Responsibilities When Outsourcing Late-Phase Studies
    11/7/2018

    A look at which departments at sponsor organizations are involved in the decision-making process and how much decision-making responsibility each department has for outsourcing various late-phase study activities.

  3. The Interconnected World Of Blockbuster Oncology Drugs
    11/7/2018

    A hypertree showing the network of connections between 2017’s top-selling oncology products. Oncology drugs made up 13 of last year’s top 50 selling products.

  4. The Top 5 Selection Drivers For Phase IV Services
    10/4/2018

    Understanding which attributes industry peers feel are important can help in the process of CRO selection.

  5. Department Influence On CMO Selection
    9/3/2018

    When it comes to CMO selection, Executive Management and Manufacturing/Production hold the most influence over the decision, each accounting for ~20% of control.

  6. Choosing A Development-Stage eCOA/ePRO Provider
    8/2/2018

    ISR asked study sponsors, CROs, and clinical research sites what’s the most important attribute they would use to select an eCOA (electronic clinical outcomes assessment)/ePRO (electronic patient reported outcomes) provider for development-stage products.

  7. What Are The Largest Slices Of The 2018 CRO Market?
    7/5/2018

    2017 was another strong year for CRO growth, with all major/public service providers experiencing year-over-year revenue gains. The largest component of CRO market revenue by geography, development, and service line is highlighted here.

  8. Is The U.S. Biosimilar Industry Falling Behind?
    6/1/2018

    Eighty-seven percent of global biosimilar sales come from the E.U., compared to just 2 percent from the U.S. We asked outsourced biomanufacturing decision-makers from North America and Europe to share their companies’ stances on selling and manufacturing biosimilars.

  9. Trial Data Collection: Paper Vs. Electronic
    5/2/2018

    The use of electronic data collection tools is prevalent across clinical trial phases. Respondents with visibility into Phase 4 studies report 90 to 96% of these studies use electronic data capture tools, either exclusively or as part of a hybrid EDC/paper strategy.

  10. 10 Years Of CRO Performance
    4/6/2018

    The 10th Edition of ISR’s CRO Quality Benchmarking Suite comes out this year. Here we take a look at how the CRO landscape has changed throughout the past decade.